President Donald Trump on Saturday directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine. which was recently adopted from Combat veterans and conservative lawmakers despite serious security risks.
Ibogaine and other psychedelics remain banned in the federal government’s strictest category of high-risk illicit drugs. But the government is taking steps to ease restrictions and advance research into using the drugs for medical purposes, including conditions such as major depression.
“Today’s order will ensure that people suffering from debilitating symptoms finally have the chance to reclaim their lives and live happier lives,” Trump said as he signed a statement Implementing regulation on drugs. The Republican president said his directive will help “dramatically accelerate” access to potential treatments. “If they turn out to be as good as people say, that will have a huge impact,” he said.
Veterans Organizations And Psychedelic drug advocate have long claimed that ibogaine, made from a shrub native to West Africa, holds promise for treating difficult-to-treat conditions such as post-traumatic stress disorder and opioid addiction.
Trump’s announcement follows promises from Secretary of Health Robert F. Kennedy Jr. and other administration officials to increase access to psychedelics for medical purposes, an issue that has rarely garnered bipartisan support.
Trump was joined in the Oval Office by his top health officials, conservative podcaster Joe Rogan and Marcus Luttrell, the former Navy SEAL whose memoirs about a deadly mission in Afghanistan were the basis of the film “Lone Survivor.” Rogan said he texted Trump information about ibogaine, and the president replied: “Sounds great. Do you want FDA approval? Let’s do it.”
“You’re going to save a lot of lives by doing this,” Luttrell told Trump during the ceremony. “It absolutely changed my life for the better.”
The Food and Drug Administration will issue national priority vouchers for three psychedelics next week, which the agency’s commissioner, Marty Makary, said will allow for rapid approval of certain drugs “if they align with our national priorities.” The vouchers can reduce the verification time from several months to several weeks. It is the first time the FDA has offered this fast tracking for psychedelics.
The FDA is also taking steps to pave the way for the first human trials of ibogaine in the United States
Trump’s actions surprised many long-time advocates and researchers in the psychedelic fieldbecause ibogaine is known to sometimes cause potentially fatal heart problems. The National Institutes of Health briefly funded research on the drug in the 1990s, but stopped the work due to ibogaine’s “cardiovascular toxicity.”
“Ibogaine has been incredibly difficult to study in the United States because of its known cardiotoxicity,” said Frederick Barrett, director of the Johns Hopkins Center for Psychedelic and Consciousness Research. “If the executive order can pave the way for objective, scientific research on this compound, it would help us understand whether it is truly a better psychedelic therapy than others.”
No psychedelic has been approved in the United States, but some of them are being studied in large trials for various mental health conditions, including: Psilocybin, MDMA And LSD. All of these drugs remain illegal and are classified as Schedule I substances alongside drugs such as heroin. Two states – Oregon And Colorado – have legalized psychedelic therapy with psilocybin.
Ibogaine was first used by members of the Bwiti religion in African countries such as Gabon during their religious ceremonies.
In recent years, U.S. veterans have reported benefiting from the drug after visiting clinics in Mexico that administer it.
Support from veterans groups and former Texas Gov. Rick Perry led to legislation last year that allocated $50 million for ibogaine research in the state. Perry, co-founder of a group called Americans for Ibogaine, recently appeared on Rogan’s podcast and advocated for lowering federal limits on the drug. It was the second time in the last two years that he spoke about ibogaine on the popular podcast.
Trump’s order calls on the Department of Health and Human Services to transfer at least $50 million to states that have established or are developing programs to promote psychedelic medications for serious mental illnesses. It is described as a federal-state partnership that provides funding, technical assistance and data sharing.
Ibogaine is known to cause irregular heart rhythms and has been linked to more than 30 deaths in the medical literature, according to the Multidisciplinary Association for Psychedelic Studies, a nonprofit organization that has conducted some early studies on patients outside the United States
The group’s co-executive director, Ismail Lourido Ali, said Trump’s order could encourage other states to follow the Texas model.
“The stigma surrounding Schedule I drugs is significant,” Ali said. “It feels like this gives Republican governors and legislators a pretty big incentive to step into the ring when it comes to funding research programs at their universities.”
Ibogaine clinic owners said the impact of the order would not be immediate.
“There will be no insurance coverage, it will continue to be considered an unapproved and non-covered treatment,” said Tom Feegel of Beond Ibogaine, which operates a clinic in Cancun, Mexico. “But what it means is that ibogaine goes from being a fringe and underground drug to a federally recognized drug.”
Feegel says his clinic treated 2,000 people with ibogaine last year for $15,000 to $20,000 per person. The company also provided free care to about 100 veterans.
Clinics that use the drug typically monitor patients’ heart values and have emergency medical equipment.
One of the few recent studies conducted by US researchers found that veterans treated with ibogaine showed improvement in symptoms of traumatic brain injury, including post-traumatic stress disorder, depression and anxiety. The Stanford University study was small and included 30 veterans who received the drug in Mexico. No placebo group was included for comparison, an essential feature of rigorous medical research. Patients in the study received a combination of ibogaine mixed with magnesium to reduce heart risk.
